Behavidence Overview
Behavidence is a platform designed to assist with diagnosis, monitoring, and managing of mental health using digital phenotypes. The platform shows dramatic insights about depression, ADHD and anxiety and is aimed giving the app users, caregivers and clinical therapists high accuracy tools to evaluate onset, progression and relapse of mental health conditions together with signals, data-driven insights and technology to improve and enhance therapies and quality of life In 2021, the company established R&D operations in Israel.
Latest News
growth-positive
Behavidence Unveils Clinical Findings Revealing Ability to Predict Postpartum Depression
Behavidence, a digital phenotyping company, announces new clinical findings revealing the ability of its app to predict postpartum depression in women. The app uses AI-driven algorithms to analyze behavior through app usage on mobile phones. This development adds value to advancements in the treatment of postpartum depression. Behavidence aims to improve mental health outcomes and is committed to leveraging AI and digital technology. The company is focused on creating a world where mental health is measurable, valued, and accessible to all.
Customers
growth-positive
Behavidence Closes $4.3M Seed Funding - FinSMEs
Behavidence, a provider of tools to monitor psychiatric and neurological disorders using artificial intelligence, has raised $4.3M in Seed funding. The funding will be used to develop the companys machine learning-based tools. Behavidences products are used for remote monitoring and management of mental health conditions and have been adopted by health organizations, tech companies, and government entities. The company has secured over $1 million in contracts with clients including the Department of Veterans Affairs, Discovery Health Insurance, and Essen Health Care.
Investment
growth-positive
כמה פעמים נכנסתם לאפליקציות בנייד, ומה הקשר למצבכם הנפשי?
Behavidence, an Israeli startup, uses artificial intelligence to map changes in emotional and mental states based on mobile phone usage patterns. The company, which has raised $1.3 million to date, is not positioning itself as a clinical diagnostic tool, but rather as a tool that can help users understand their mental health. The companys model has been tested on groups of people diagnosed with clinical depression, anxiety, and ADHD, achieving a 77% accuracy rate in a separate group of diagnosed individuals. The company is in talks with insurance companies interested in its product.
Investment
Team Members
2
Employees: 1-10
Web & Social Links
| Website | www.behavidence.com/ |
Locations
Tel Aviv-Yafo, Israel
9 Wall St #4004, New York, NY 10005, USA
Discovery Wy, Woodhouse, Leeds LS2, UK
Photos & Videos
1 item(s)
